Tear Substance Indicates Possible Nerve Damage in Diabetes Patients
By LabMedica International staff writers Posted on 17 Jul 2017 |
Image: A space-filling model of substance P (Photo courtesy of Wikimedia Commons).
Measurement of levels of substance P peptide in tears has been proposed as a method for determining possible nerve damage in individuals suffering from diabetes.
Substance P is a neuropeptide composed of a chain of 11 amino acid residues. It is member of the tachykinin neuropeptide family and acts as a neurotransmitter and neuromodulator. Its receptor - the neurokinin type 1 - is distributed over cytoplasmic and nuclear membranes of many cell types (neurons, glia, endothelia of capillaries and lymphatics, fibroblasts, stem cells, white blood cells) in many tissues and organs.
Investigators at the University of New South Wales (Sydney, Australia) determined total protein content and substance P concentrations in tear samples obtained from 17 healthy control individuals and nine diabetes patients. Corneal nerve fiber density, an indication of diabetes-related damage to the peripheral nerves (peripheral neuropathy), was measured by confocal microscopy.
Results revealed that while there was no significant difference in total protein content between the groups, substance P concentrations were significantly higher in the tears of the control group compared to the diabetes patients. The diabetes patients also displayed significantly lower corneal nerve fiber density, indicating loss of corneal nerve fibers. Substance P levels were moderately correlated with the corneal nerve fiber density measurements.
First author Dr. Maria Markoulli, a lecturer in optometry and vision science at the University of New South Wales, said, "The positive correlation between substance P and corneal nerve density indicates that substance P may be a potential biomarker for corneal nerve health."
The study was published in the July 7, 2017, issue of the journal Optometry and Vision Science.
Related Links:
University of New South Wales
Substance P is a neuropeptide composed of a chain of 11 amino acid residues. It is member of the tachykinin neuropeptide family and acts as a neurotransmitter and neuromodulator. Its receptor - the neurokinin type 1 - is distributed over cytoplasmic and nuclear membranes of many cell types (neurons, glia, endothelia of capillaries and lymphatics, fibroblasts, stem cells, white blood cells) in many tissues and organs.
Investigators at the University of New South Wales (Sydney, Australia) determined total protein content and substance P concentrations in tear samples obtained from 17 healthy control individuals and nine diabetes patients. Corneal nerve fiber density, an indication of diabetes-related damage to the peripheral nerves (peripheral neuropathy), was measured by confocal microscopy.
Results revealed that while there was no significant difference in total protein content between the groups, substance P concentrations were significantly higher in the tears of the control group compared to the diabetes patients. The diabetes patients also displayed significantly lower corneal nerve fiber density, indicating loss of corneal nerve fibers. Substance P levels were moderately correlated with the corneal nerve fiber density measurements.
First author Dr. Maria Markoulli, a lecturer in optometry and vision science at the University of New South Wales, said, "The positive correlation between substance P and corneal nerve density indicates that substance P may be a potential biomarker for corneal nerve health."
The study was published in the July 7, 2017, issue of the journal Optometry and Vision Science.
Related Links:
University of New South Wales
Latest Molecular Diagnostics News
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset